
MiMedx Group Inc
NASDAQ:MDXG

Intrinsic Value
The intrinsic value of one
MDXG
stock under the Base Case scenario is
6.77
USD.
Compared to the current market price of 7.17 USD,
MiMedx Group Inc
is
Overvalued by 6%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
MiMedx Group Inc
Fundamental Analysis


Revenue & Expenses Breakdown
MiMedx Group Inc
Balance Sheet Decomposition
MiMedx Group Inc
Current Assets | 200.1m |
Cash & Short-Term Investments | 106.4m |
Receivables | 62.3m |
Other Current Assets | 31.4m |
Non-Current Assets | 70.3m |
PP&E | 11.1m |
Intangibles | 30.5m |
Other Non-Current Assets | 28.7m |
Free Cash Flow Analysis
MiMedx Group Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
MiMedx Group Inc
Revenue
|
352.4m
USD
|
Cost of Revenue
|
-63.6m
USD
|
Gross Profit
|
288.7m
USD
|
Operating Expenses
|
-243.4m
USD
|
Operating Income
|
45.3m
USD
|
Other Expenses
|
-5.1m
USD
|
Net Income
|
40.2m
USD
|
MDXG Profitability Score
Profitability Due Diligence
MiMedx Group Inc's profitability score is 61/100. The higher the profitability score, the more profitable the company is.

Score
MiMedx Group Inc's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
MDXG Solvency Score
Solvency Due Diligence
MiMedx Group Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Score
MiMedx Group Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MDXG Price Targets Summary
MiMedx Group Inc
According to Wall Street analysts, the average 1-year price target for
MDXG
is 12.24 USD
with a low forecast of 11.11 USD and a high forecast of 13.65 USD.
Dividends
Current shareholder yield for MDXG is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
MDXG
stock under the Base Case scenario is
6.77
USD.
Compared to the current market price of 7.17 USD,
MiMedx Group Inc
is
Overvalued by 6%.